Partial ablation of mu-opioid receptor rich striosomes produces deficits on a motor-skill learning task.
Basal ganglia striosomes, or patches, are rich in mu opioid receptors (MOR) and form a three-dimensional labyrinth of cells that extend throughout the mid- and anterior striatum in mice. Though previous studies have suggested that striosomes could affect drug-induced motor output in rodents, the functional role of these compartmentalized MOR-rich striosomes is not well understood. To investigate any relationship between the striosomes and motor behavior we used the toxin dermorphin-saporin (DS) to selectively ablate MOR-rich striosomal cells. FVB mice were bilaterally infused with DS in the midstriatum alone or in the mid- and anterior striatum, and were tested on three motor tasks and in an open field. Two volume measurement procedures and stereological cell counts were used to confirm the induced pathology. Mice that received DS injections showed significantly smaller volumes (-26% to -44%) and fewer cells (-30% to -49%) in the striosome compartment compared to mice that received control injections of saline or saporin. Striosome pathology was greatest in the dorsolateral striatum. The extrastriosomal matrix was not significantly affected, resulting in an imbalance in the ratio of striosome-to-matrix cells. Behaviorally, toxin injections caused deficits on an accelerating rotarod task and the deficit was worse in mice that received mid and anterior injections than those that received midstriatal injections alone. However, DS-injected mice did not differ from control mice on other motor tasks. We conclude that the MOR-rich cells of the striosomes are necessary for optimal rotarod performance, including learning and/or improvement on the task.
Lawhorn
C
C
Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Kennedy Center, 1300 Morris Park Avenue, Bronx, NY 10461, USA. clawhorn@rockefeller.edu
Smith
D M
DM
Brown
L L
LL
D000701:Analgesics, Opioid; D000818:Animals; D002452:Cell Count; D003714:Denervation; D015536:Down-Regulation / Q000187:drug effects / Q000502:physiology; D004409:Dyskinesia, Drug-Induced / Q000378:metabolism / Q000503:physiopathology; D000922:Immunotoxins; D007858:Learning / Q000502:physiology*; D007859:Learning Disabilities / Q000139:chemically induced / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D051379:Mice; D009048:Motor Skills / Q000502:physiology*; D017072:Neostriatum / Q000166:cytology / Q000378:metabolism*; D009410:Nerve Degeneration / Q000139:chemically induced / Q000378:metabolism / Q000503:physiopathology; D009474:Neurons / Q000166:cytology / Q000378:metabolism*; D009483:Neuropsychological Tests; D018847:Opioid Peptides; D017450:Receptors, Opioid, mu / Q000378:metabolism*; D054789:Ribosome Inactivating Proteins, Type 1; D000076985:Saporins
D000701:Analgesics, Opioid; D000922:Immunotoxins; D018847:Opioid Peptides; D017450:Receptors, Opioid, mu; D054789:Ribosome Inactivating Proteins, Type 1; C030058:dermorphin; D000076985:Saporins